Tatva Chintan Pharma Chem Limited

Tatva Chintan Pharma Chem Ltd. Q3 FY26 Earnings Call Transcript Released

Tatva Chintan Pharma Chem reported Q3 FY26 revenue of ₹1,313 million (up 53% YoY) and EBITDA of ₹255 million (up 261% YoY). The company plans a new plant at Jolva, Dahej, with ₹250-275 crore capex, expected operational within 18 months. They anticipate ₹850-900 crore revenue in 2.5-3 years and 20-30% annual growth.

Tatva Chintan Pharma Chem Limited Publishes Financial Results Extract in Newspapers

Tatva Chintan Pharma Chem Limited published extracts of its financial results for the quarter and nine months ended December 31, 2025. The results were published in the Financial Express and Vadodara Samachar on January 22, 2026. The information is also available on the company's website.

Tatva Chintan Pharma Chem Limited: Earnings Call Recording Available

Tatva Chintan Pharma Chem Limited has made the recording of their Earnings Call held on January 21, 2026, available on their website. This follows SEBI regulations and provides investors access to the discussion from the call.

Tatva Chintan Pharma Chem Ltd. Presents Q3 FY26 Investor Presentation

Tatva Chintan Pharma Chem Ltd. reported strong Q3 FY26 results. Revenue grew 53% YoY to ₹131.3 crore. PAT surged 10,889% YoY to ₹15.2 crore. For 9MFY26, revenue increased 35% YoY to ₹371.7 crore, and PAT grew 578% YoY to ₹31.7 crore. The company highlighted its diversified product portfolio and international presence.

Tatva Chintan Pharma Chem Schedules Q3FY26 Earnings Call for Jan 21, 2026

Tatva Chintan Pharma Chem Limited will hold its Q3FY26 earnings call on January 21, 2026, at 5:00 PM IST, post the announcement of financial results for the quarter and nine months ended December 31, 2025. The call will be hosted by ICICI Securities.

Tatva Chintan Pharma Chem Receives SEBI Compliance Certificate for Q3 FY26

Tatva Chintan Pharma Chem Limited received a compliance certificate for the quarter ended December 31, 2025. The certificate from MUFG Intime India Private Limited confirms adherence to SEBI (Depositories and Participants) Regulations, 2018, regarding the processing of dematerialized securities.

Tatva Chintan Pharma Chem Limited: Trading Window Closure from Jan 1, 2026

Tatva Chintan Pharma Chem Limited announced a trading window closure for designated persons and their relatives. The window will be closed from January 1, 2026, until 48 hours after the declaration of Q3 FY26 financial results.

Intimation of Investor Meeting on 26 Nov 2025

Tatva Chintan Pharma Chem Limited announces investor meeting with Sequent Investments on 26 November 2025, to be held virtually. The company will only discuss publicly available information.

Intimation of Investor Meeting on 21 Nov 2025

Tatva Chintan Pharma Chem Limited announced an investor meeting with Xponent Tribe on 21 November 2025 via virtual mode. The company will refer to publicly available information during the meeting.

Tatva Chintan Pharma Chem to hold investor meeting with Singularity AMC on November 20, 2025

Tatva Chintan Pharma Chem will hold a physical one-on-one meeting with Singularity AMC on November 20, 2025, discussing publicly available information.

Intimation of Investor Meeting on 17 Nov 2025

Tatva Chintan Pharma Chem Limited informed about their participation in an investor meeting with Courser Park Advisors LLP on 17 November 2025 through virtual mode.

Tatva Chintan Pharma Chem to hold virtual investor meeting with EastLane Capital LLP

Tatva Chintan Pharma Chem will conduct a virtual one-on-one meeting with EastLane Capital LLP on November 13, 2025, discussing only publicly available information.

Tatva Chintan Pharma Chem to meet IWealth Management LLP on November 12, 2025

Tatva Chintan Pharma Chem to hold a virtual one-on-one meeting with IWealth Management LLP on November 12, 2025, discussing only public information.

Intimation of Investor Meeting on 11 Nov 2025

Tatva Chintan Pharma Chem Limited announced an investor meeting with Carnelian Asset Management & Advisors Pvt Ltd on 11 November 2025. The meeting will be virtual and one-on-one.

Intimation of Investor Meeting on 12 Nov 2025

Tatva Chintan Pharma Chem Limited is scheduled to have an investor meeting with SBI Funds Management Private Limited on 12 November 2025.

Tatva Chintan Q2 FY26 Earnings Call Transcript

Tatva Chintan Pharma Chem Limited releases the transcript of its Q2 FY26 earnings conference call held on October 31, 2025, following the announcement of its financial results.

Newspaper Publication of Financial Results for Quarter Ended 30 Sep 2025

Tatva Chintan Pharma Chem Limited announced the publication of its financial results for the quarter and half year ended September 30, 2025, in Financial Express and Vadodara Samachar on November 1, 2025.

Tatva Chintan Pharma Chem Limited announces availability of Earnings Call recording

Tatva Chintan Pharma Chem Limited announced the recording of its Earnings Call held on October 31, 2025, is now available on the company's website for investor access.

Tatva Chintan Announces Investor Presentation for Q2FY26

Tatva Chintan announced its investor presentation for Q2FY26, showcasing revenue of ₹1,23.5 million, a 48% YoY increase, and PAT of ₹99 million, a 1,594% YoY increase.

Tatva Chintan Pharma Chem Authorizes KMPs for Materiality Disclosures

Tatva Chintan Pharma Chem Limited's Board authorized five Key Managerial Personnel (KMPs) to determine materiality of events for stock exchange disclosures as per SEBI regulations on 31 October 2025.

Tatva Chintan Approves Unaudited Financial Results & Appoints CFO

Tatva Chintan approves unaudited financial results for the quarter ended September 30, 2025, and appoints Ajesh Kumar Mohanan Pillai as CFO, effective October 31, 2025.

TATVA Announces Q2 & H1 Results, CFO Appointment

Tatva Chintan approves Q2 & H1 results, appoints Ajesh Kumar Mohanan Pillai as CFO effective 31 October 2025. The board has reviewed the standalone and consolidated results.

Tatva Chintan Pharma Chem clarifies on recent share price movement

Tatva Chintan Pharma Chem clarified to stock exchanges that recent share price movement is market-driven, with no undisclosed material information withheld by the company.

Tatva Chintan Pharma Chem Limited Announces Q2FY26 Results Conference Call

Tatva Chintan Pharma Chem Limited is conducting an earnings call on 31 October 2025 at 5 PM IST to discuss Q2 and Half Year ended 30 September 2025 financial results. The call will be hosted by ICICI Securities.

Compliance Certificate under SEBI Regulations 2018

Tatva Chintan Pharma Chem Limited submitted a compliance certificate under SEBI regulations for the quarter ended September 30, 2025.

Tatva Chintan Pharma Chem Limited held 29th Annual General Meeting

Tatva Chintan Pharma Chem Limited to hold investor meeting

Newspaper Publication for 29th Annual General Meeting

Tatva Chintan Pharma Chem Announces Record Date, Book Closure, and Cut-off for 29th AGM and FY25 Final Dividend

Tatva Chintan Pharma Chem Submits FY25 Business Responsibility and Sustainability Report, Details ESG Initiatives

Tatva Chintan Launches 'Saksham Niveshak' Campaign for Unclaimed Dividends

Tatva Chintan Q1 FY26 Revenue Up 11% YoY, EBITDA Rises 37%

Tatva Chintan Pharma Chem announces Earnings Call recording available

Tatva Chintan Pharma Chem Reports Robust Q1 FY26 Performance with Significant Profit Surge

Tatva Chintan: CFO Resigns, Board Approves Re-appointments and Financial Results

Tatva Chintan reports strong Q1 FY26 results; re-appoints key directors, CFO resigns